Monica Corazza: Influence Statistics

Monica Corazza

Monica Corazza

Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Via L. Ariosto 35, 44121, Ferrara, Italy | Section of Dermatology and ...

Monica Corazza: Expert Impact

Concepts for which Monica Corazza has direct influence: Allergic contact dermatitis , Allergic contact , Contact dermatitis , Vulvar lichen sclerosus , Lichen sclerosus , Patch tests , Mometasone furoate .

Monica Corazza: KOL impact

Concepts related to the work of other authors for which for which Monica Corazza has influence: Contact dermatitis , Lichen sclerosus , Hidradenitis suppurativa , Patch testing , Sweet syndrome , Dermoscopic features , Pediatric psoriasis .

KOL Resume for Monica Corazza

Year
2022

Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Via L. Ariosto 35, 44121, Ferrara, Italy

University of Ferrara: Universita degli Studi di Ferrara

2021

Sezione di Dermatologia, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Ferrara, Italy

2020

Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Via L. Ariosto 35, 44121 Ferrara, Italy

2019

Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, 44124, Italy

2018

Dipartimento di Scienze Mediche, Sezione di Dermatologia, Università degli Studi di Ferrara, Italy

2017

Dipartimento di Scienze Mediche, Sezione di Dermatologia, Università di Ferrara, Ferrara, Italy

Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara

2016

Section of Dermatology, Department of Clinical and Experimental Medicine University of Ferrara Ferrara Italy

2015

Dipartimento di Scienze Mediche Sezione di Dermatologia e Malattie Infettive Università degli Studi di Ferrara alessandro.borghi@unife.it

University of Ferrara Department of Medical Science, Unit of Dermatology and Infectious Diseases Ferrara Italy

2014

Department Medical Sciences, Section of Dermatology, University of Ferrara, Via Savonarola 9, IT-44123 Ferrara, Italy.

Sezione di Dermatologia e Malattie Infettive, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara

2013

University of Ferrara, I‐44121 Department of Medical Sciences, Section of Dermatology Ferrara Italy

2012

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Ferrara, Italy

2011

Section of Dermatology, Department of Clinical and Experimental Medicine, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

2010

From the Department of Clinical and Experimental Medicine, Section of Dermatology, and the Department of Pharmaceutical Science, University of Ferrara, Ferrara, Italy. Address reprint requests to Maria Michela Lauriola, Department of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy. E‐mail: michelalrl@gmail.com

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Via Savonarola 9, Ferrara, Italy.

2009

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Italy.

2008

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

2006

Department of Clinical and Experimental Medicine, Section of Dermatology, and

2005

Department of Clinical and Experimental Medicine – Section of Dermatology, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

2004

Dipartimento Di Medicina Clinica e Sperimentale-Sezione di Dermatologia, Universita’ Degli Studi Di Ferrara, Via Savonarola, 9-44100, Ferrara, Italia

Department of Dermatology, University of Ferrara, Ferrara, Italy

2003

Dipartimento di Medicina Clinica e Sperimentale – Sezione Dermatologia, Università di Ferrara,

2002

Department of Clinical and Experimental Medicine‐Section of Dermatology, University of Ferrara, Ferrara, Italy

Dipartimento di Medicina Clinica e Sperimentale‐ Sezione Dermatologia, Università di Ferrara,

2001

Dipartimento di Medicina Clinica e Sperimentale, Sezione di Dermatologia, Università degli Studi di Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

2000

Dipartimento Medicina Clinica e Sperimentale-Sezione Dermatologia, Università degli Studi di Ferrara, Via Savonarola 9, 44100 Ferrara, Italy.

1999

Clinica Dermatologica, Università di Ferrara, Via Savonarola, 9, 44100Ferrara, Italy

1998

Dipartimento Medicina Clinica e Sperimentale, Sezione Dermatologia, Universita di Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

1997

Clinica Dermatologica, Università degli Studi di Ferrara, Via Savonarola 9, 44100 Ferrara, Italy

1996

Clinica dermatologica, Universita degli studi di Ferrara. Via Savonarola 9, 44100 Ferrara, Italy

1995

Clinica Dermotologica, Università di Ferrara, Via Savonarola 9, 44100 ferrara, Italy

1993

Clinica Dermatologica, Universitá di Ferrara. Via Savonarola 9, 44100 Ferrara. Italy

Prominent publications by Monica Corazza

KOL-Index: 12997 . BACKGROUND: A 3-month topical application of clobetasol propionate (CP) represents the recommended and accepted first-line treatment for vulvar lichen sclerosus (VLS); however, to date, no randomized controlled trials have compared the efficacy and safety of CP with other topical corticosteroids. OBJECTIVE: To compare the effectiveness and tolerability of two different topical ...
Known for Mometasone Furoate | Clobetasol Propionate | Vulvar Lichen Sclerosus | Treatment Vls
KOL-Index: 10488 . IMPORTANCE: The molecular mechanism leading to the development of vulvar squamous cell carcinoma (VSCC) from vulvar lichen sclerosus (VLS) is unknown. OBJECTIVE: To assess the possible involvement of the IRF6 tumor-suppressor gene in the development of VSCC from VLS. DESIGN: In laboratories at the University of Ferrara, Ferrara, Italy, IRF6 gene expression and promoter methylation were ...
Known for Cell Carcinoma | Vulvar Squamous | Promoter Methylation | Lichen Sclerosus
KOL-Index: 9269 . BACKGROUND: The chronic and relapsing nature of vulvar lichen sclerosus (VLS) represents a challenge for its long-term management after an effective treatment with topical corticosteroids. OBJECTIVES: To assess the effectiveness of proactive, twice-weekly application of mometasone furoate 0·1% ointment, compared with daily topical vitamin E or cold cream, in keeping VLS in remission and ...
Known for Topical Corticosteroid | Mometasone Furoate | Vulvar Lichen | 0·1 Ointment
KOL-Index: 8274 . ObjectiveThe objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks.MethodsA retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. Inclusion criteria were: age ≥ 65 years; diagnosis of ...
Known for Atopic Dermatitis | Dupilumab Treatment | Elderly Patients | Effectiveness Safety
KOL-Index: 8157 . BACKGROUND: Few reports have addressed the associations between clinical, demographic and historical variables of vulvar lichen sclerosus (VLS). OBJECTIVE: To elaborate the prevalence and severity of signs and symptoms and to identify potential factors predicting the severity and course of VLS. METHODS: A prospective cohort of 225 patients affected by VLS was included. Data were collected ...
Known for Vulvar Lichen | Severity Vls | Age Onset | Patients Symptoms
KOL-Index: 7082 . BACKGROUND: Topical corticosteroids are the first-line treatment for vulvar lichen sclerosus (VLS). However, evidence on the most appropriate treatment regimen is lacking. OBJECTIVES: To compare the effectiveness and tolerability of tapering vs. continuous application of mometasone furoate (MMF) 0·1% ointment in the treatment of active VLS. METHODS: Sixty-four patients with VLS who ...
Known for Mometasone Furoate | Vulvar Lichen Sclerosus | Subjective Objective Scores | Active Vls
KOL-Index: 7054 . BACKGROUND: Chronic inflammatory vulvar diseases can have a huge detrimental impact on patient welfare. A few studies have addressed this issue so far, mainly measuring patients' quality of life or sexual dysfunction. OBJECTIVE: To assess the burden of suffering in patients with chronic inflammatory vulvar diseases using the Pictorial Representation of Illness and Self-Measure (PRISM), a ...
Known for Pictorial Representation | Prism Dlqi | Perceived Burden | Life Quality
KOL-Index: 7014 . BACKGROUND: Acitretin is licensed for and is most commonly used to treat psoriasis. Little information exists about its efficacy and safety in childhood and adolescent psoriasis. METHODS: Retrospective analysis of a group of children and adolescents (<17 years of age) with moderate to severe plaque psoriasis treated with acitretin between 2010 and 2014 at Italian dermatology clinics. ...
Known for Plaque Psoriasis | Retrospective Analysis | Patients Acitretin | Treatment Children
KOL-Index: 6945 . BACKGROUND: Guidelines identify a 3-month topical application of an ultra-potent corticosteroid ointment as the mainstay of medical treatment for vulvar lichen sclerosus (VLS). However, there are no trials providing evidence that any specific corticosteroid is superior to another. OBJECTIVE: To assess the effectiveness and safety of a 12-week application of mometasone furoate (MMF) 0.1% ...
Known for Vulvar Lichen Sclerosus | 01 Ointment | Mometasone Furoate | Patients Vls
KOL-Index: 6851 . BACKGROUND: Twice-weekly proactive application of mometasone furoate 0.1% ointment (MMF) over 52 weeks was found to be an effective and safe therapy option in maintaining vulvar lichen sclerosus (VLS) remission and in preventing relapse. OBJECTIVE: To assess and compare the effectiveness and safety of two different topical corticosteroids, clobetasol propionate 0.05% ointment (CP) and MMF, ...
Known for Mometasone Furoate | Clobetasol Propionate | Vulvar Lichen Sclerosus | Vls Mmf
KOL-Index: 6616 . BACKGROUND: The evidence on the safety of topical preparations containing botanical extracts is limited. OBJECTIVES: To assess (i) the use of botanically derived compounds in a large population, (ii) the incidence of cutaneous side-effects, and (iii) the diagnostic usefulness of patch testing. METHODS: A questionnaire was used in 2661 patients to assess both the prevalence and type of ...
Known for Patch Tests | Skin Reactions | Allergic Contact Dermatitis | Contact Allergy
KOL-Index: 6339 . BACKGROUND: Contact dermatitis (CD) is a chronic disease with a significant impact on quality of life (QoL). There have been relatively few reports in the literature on specific QoL outcomes for patients suffering from CD. OBJECTIVES: To develop a new instrument specifically designed to measure QoL in CD and to investigate which disease features could strongly influence QoL. METHODS: Three ...
Known for Contact Dermatitis | Disease‐specific Questionnaire | Quality Life | Illness Surveys
KOL-Index: 6072 . Patch testing is the standard procedure used to diagnose allergic contact dermatitis. It is an in-vivo test, which reproduces the reaction to a contact allergen. This in-vivo test aims to reproduce the elicitation phase of allergic contact dermatitis and is performed applying allergens under occlusion on the skin under standardized conditions. These guidelines for the best practice in ...
Known for Contact Dermatitis | Patch Testing | Italian Guidelines | Humans Italy
KOL-Index: 5884 . BACKGROUND: According to the current guidelines, the aim of vulvar lichen sclerosus (VLS) treatment was to improve symptoms and signs, not to cure. OBJECTIVE: To assess (i) the rate of patients with VLS who achieved complete clearance of symptoms or objective features, or both, with a 12-week pharmacological treatment and (ii) the predictive value of therapeutic response to the demographic ...
Known for Vulvar Lichen Sclerosus | Complete Clearance | Vls Patients | 12 Weeks

Key People For Allergic Contact Dermatitis

Top KOLs in the world
#1
Howard Ira Maibach
contact dermatitis percutaneous absorption human skin
#2
Klaus Ejner Andersen
allergic contact dermatitis contact allergy hand eczema
#3
Torkil Menné
hand eczema contact allergy atopic dermatitis
#4
Jeanne Duus Duus Johansen
contact allergy hand eczema atopic dermatitis
#5
Magnus Magnus
cas registry contact allergy patch testing
#6
Wolfgang J C Uter
contact allergy patch test european surveillance

Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Via L. Ariosto 35, 44121, Ferrara, Italy | Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, F